Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Study on the efficacy of the growth inhibitors after endoscopic treatment of acute esophagogastric variceal bleeding
Participants with acute esophagogastric variceal bleeding in 5 days and under stable status will be included in this study. All the patients will take CTP test to confirm the blood flow status of the portal vein before endoscopic treatment. After that they will be randomly divided into two groups: A. accept growth inhibitors after the endoscopic treatment for 5 days; B. no growth inhibitor will be applied after the treatment.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group A | Experimental | Participants in this group will take growth inhibitors for 5 days after endoscopic treatment. |
|
| Group B | No Intervention | Participants in this group will not take growth inhibitor treatment after endoscopic treatment. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Growth Inhibitor | Drug | growth inhibitors for 250-500μg/h, ivgtt. for 5 days |
|
| Measure | Description | Time Frame |
|---|---|---|
| rebleeding rate after the endoscopic treatment in Group A at 1 month | record the rebleeding incidence in this group A; (Rate A1= the number of rebleeding participants/the number of all the participants) | 1 month after the endoscopic treatment |
| rebleeding rate after the endoscopic treatment in Group A at 3 months | record the rebleeding incidence in this group A; (Rate A2= the number of rebleeding participants/the number of all the participants) | 3 months after the endoscopic treatment |
| rebleeding rate after the endoscopic treatment in Group A at 6 months | record the rebleeding incidence in this group A; (Rate A3= the number of rebleeding participants/the number of all the participants) | 6 months after the endoscopic treatment |
| rebleeding rate after the endoscopic treatment in Group B at 1 month | record the rebleeding incidence in this group B; (Rate B1= the number of rebleeding participants/the number of all the participants) | 1 month after the endoscopic treatment |
| rebleeding rate after the endoscopic treatment in Group B at 3 months | record the rebleeding incidence in this group B; (Rate B2= the number of rebleeding participants/the number of all the participants) | 3 months after the endoscopic treatment |
| rebleeding rate after the endoscopic treatment in Group B at 6 months | record the rebleeding incidence in this group B; (Rate B3= the number of rebleeding participants/the number of all the participants) |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| WEI WEI | Contact | 15267175186 | wwze@zju.edu.cn |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| 2nd Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | Hanzhou | Zhejiang | 310000 | China |
on request
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006131 | Growth Inhibitors |
| ID | Term |
|---|---|
| D006133 | Growth Substances |
| D045505 | Physiological Effects of Drugs |
| D020228 | Pharmacologic Actions |
| D020164 | Chemical Actions and Uses |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 6 months after the endoscopic treatment |